Concurrent vs sequential adjuvant chemotherapy and hormone therapy in breast cancer: A multicenter randomized phase III trial

Journal of the National Cancer Institute

Volumn 103, Issue 20, 2011, Pages 1529-1539

  Bedognetti, Davide ^a,b   Sertoli, Mario Roberto ^a,b   Pronzato, Paolo ^a   Del Mastro, Lucia ^a   Venturini, Marco ^a,d   Taveggia, Paola ^a   Zanardi, Elisa ^a,b   Siffredi, Guido ^a,b   Pastorino, Simona ^a   Queirolo, Paola ^a   Gardin, Giovanni ^a   Wang, Ena ^c   Monzeglio, Clara ^e   Boccardo, Francesco ^a,b   Bruzzi, Paolo ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

^e Department of Obstetrics and Gynecology   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; HORMONE RECEPTOR; METHOTREXATE; TAMOXIFEN;

ADULT; AGE; ALOPECIA; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER STAGING; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG FATALITY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LEUKOPENIA; LYMPH NODE; MAJOR CLINICAL STUDY; MENOPAUSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; THROMBOCYTOPENIA;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AXILLA; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CONFOUNDING FACTORS (EPIDEMIOLOGY); CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; GLUCURONATES; HUMANS; ITALY; KAPLAN-MEIER ESTIMATE; LYMPH NODE EXCISION; MASTECTOMY, SEGMENTAL; METHOTREXATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS; TAMOXIFEN; TREATMENT OUTCOME;

EID: 80054933718     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr351     Document Type: Article

References (38)

1. Abe O, Abe R, Enomoto K, et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-1717.
2. Sertoli MR, Scarsi PG, Rosso R. Rationale for combining chemotherapy and hormonal therapy in breast cancer. J Steroid Biochem. 1985;23(6B):1097-1103. (Pubitemid 16160205)
3. Osborne CK, Kitten L, Arteaga CL. Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens. J Clin Oncol. 1989;7(6):710-717. (Pubitemid 19145591)
4. Hug V, Hortobagyi GB, Drewinko B, Finders M. Tamoxifen-citrate counteracts the antitumor effects of cytotoxic drugs in vitro. J Clin Oncol. 1985;3(12):1672-1677. (Pubitemid 16199219)
5. Osborne CK. Combined chemo-hormonal therapy in breast cancer: a hypothesis. Breast Cancer Res Treat. 1981;1(2):121-123. (Pubitemid 12170038)
6. Leonessa F, Jacobson M, Boyle B, Lippman J, McGarvey M, Clarke R. Effect of tamoxifen on the multidrug-resistant phenotype in human breast cancer cells: isobologram, drug accumulation, and M(R)-170,000 glycoprotein (Gp170) binding studies. Cancer Res. 1994;54(2):441-447.
7. Kurebayashi J, Nukatsuka M, Nagase H, et al. Additive antitumor effect of concurrent treatment of 4-hydroxy tamoxifen with 5-fluorouracil but not with doxorubicin in estrogen receptor-positive breast cancer cells. Cancer Chemother Pharmacol. 2007;59(4):515-525. (Pubitemid 46122330)
8. Benz C, Cadman E, Gwin J, et al. Tamoxifen and 5-fluorouracil in breast cancer: cytotoxic synergism in vitro. Cancer Res. 1983;43(11):5298-5303.
9. Pritchard KI. Combining endocrine agents with chemotherapy: which patients and what sequence? Cancer. 2008;112(3):718-722. (Pubitemid 351186394)
10. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47(1):207-214. (Pubitemid 11167383)
11. Wager E, Tooley PJ, Emanuel MB, Wood SF. How to do it. Get patients' consent to enter clinical trials. BMJ. 1995;311(7007):734-737.
12. Sertoli MR, Bruzzi P, Pronzato P, et al. Randomized cooperative study of perioperative chemotherapy in breast cancer. J Clin Oncol. 1995;13(11):2712- 2721.
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457-481.
14. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50(3):163-170.
15. Cox DR. Regression models and life-tables. J R Stat Soc Series B Stat Methodol. 1972;34(2):187-220.
16. Cuzick J. Forest plots and the interpretation of subgroups. Lancet. 2005;365(9467):1308.
17. Venturini M, Del Mastro L, Aitini E, et al. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. J Natl Cancer Inst. 2005;97(23):1724-1733. (Pubitemid 41782282)
18. Pronzato P, Sertoli MR, Amoroso D, et al. A randomized study of concurrent versus sequential chemotherapy and tamoxifen in stage II breast cancer. Proceeding of the Sixth International Conference on the Adjuvant Therapy of Cancer. Tucson, Arizona; 1990;1:298-304.
19. Sertoli MR, Pronzato P, Amoroso D, et al. A randomized study of concurrent versus sequential chemotherapy and tamoxifen in stage II breast cancer. Proc Am Soc Clin Oncol. 1991;10(65):48. Abstract 65.
20. Sertoli M, Pronzato P, Queirolo P, et al. A randomized study of concurrent vs sequential chemo-ormonotherapy in stage II breast cancer. Proceeding of the Fourth International Conference on the Adjuvant Therapy of Primary Breast Cancer. St. Gallen, Switzerland; 1992. Abstract 71.
21. Sertoli MR, Pronzato P, Venturini M, et al. A randomized study of concurrent versus sequential adjuvant chemotherapy and tamoxifen in stage II breast cancer. Proc Am Soc Oncol. 2002;21(182):46. Abstract 182.
22. Martin M, Segui MA, Anton A, et al. Adjuvant docetaxel for high-risk, node-negative breast cancer. N Engl J Med. 2010;363(23):2200-2210.
23. Early Breast Cancer Trialists' Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. Early Breast Cancer Trialists' Collaborative Group. N Engl J Med. 1988;319(26):1681-1692.
24. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998;351(9114):1451-1467.
25. Pico C, Martin M, Jara C, et al. Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study. Ann Oncol. 2004;15(1):79-87. (Pubitemid 38139607)
26. Albain KS, Barlow WE, Ravdin PM, et al. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009;374(9707):2055-2063.
27. Albain KS, Green SJ, Ravdin PM, et al. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100 (SWOG-8814). Proc Am Soc Clin Oncol. 2002;21(182). Abstract 143.
28. Swain SM, Jeong JH, Geyer CE, et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med. 2010;362(22):2053-2065.
29. Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol. 2005;16(10):1569-1583. (Pubitemid 41511089)
30. Fisher B, Redmond C, Legaultpoisson S, et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen : results from the National Surgical Adjuvant Breast and Bowel Project-B-16. J Clin Oncol. 1990;8(6):1005-1018. (Pubitemid 20200188)
31. Namer M, Fargeot P, Roche H, et al. Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02 and 07 trials. Ann Oncol. 2006;17(1):65-73. (Pubitemid 43033842)
32. Del Mastro L, Dozin B, Aitini E, et al. Timing of adjuvant chemotherapy and tamoxifen in women with breast cancer: findings from two consecutive trials of Gruppo Oncologico Nord-Ovest-Mammella Intergruppo (GONO-MIG) Group. Ann Oncol. 2008;19(2):299-307. (Pubitemid 351201711)
33. Aebi S, Castiglione M. The enigma of young age. Ann Oncol. 2006;17(10):1475-1477. (Pubitemid 44542031)
34. Colleoni M, Rotmensz N, Robertson C, et al. Very young women (<35 years) with operable breast cancer: features of disease at presentation, Ann Oncol, 2002; 13; 2, 273-279. (Pubitemid 34704980)
35. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol. 1991;9(2):286-294.
36. Pritchard KI, Paterson AHG, Paul NA, Zee B, Fine S, Pater J. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. J Clin Oncol. 1996;14(10):2731-2737. (Pubitemid 26329659)
37. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010;102(1):14-25.
38. Watanabe N, Ootawa Y, Kodama K, et al. Concurrent administration of chemo-endocrine therapy for postmenopausal breast cancer patients. Breast Cancer. 2010;17(4):247-253.